查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1882972

治疗性神经毒素市场规模、占有率、成长及全球产业分析：按类型、应用和地区划分的洞察与预测（2024-2032）

Therapeutic Neurotoxin Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 309 Pages | 商品交期: 请询问到货日

价格

治疗性神经毒素市场成长因素

受神经系统疾病盛行率上升以及肉毒桿菌疗法在各医疗专科的快速普及推动，全球治疗性神经毒素市场正稳步扩张。根据本报告预测，该市场规模预计将在2024年达到58.6亿美元，并在2025年增长至63.4亿美元。预计到2032年，该市场规模将达到112.2亿美元，预测期内复合年增长率（CAGR）为8.5%。 2024年，北美地区占了72.6%的市场占有率，这主要得益于其先进的医疗保健体係以及对治疗性神经毒素在各种适应症中的早期应用。

治疗性神经毒素（主要是A型和B型肉毒桿菌毒素）广泛用于治疗慢性偏头痛、颈肌张力失调、眼睑痉挛、痉挛和膀胱过动症等神经系统疾病。其作用机转为阻断神经肌肉传递，进而减轻肌肉过度活动及相关症状。艾伯维、益普生製药、默兹製药和瑞凡斯製药等主要公司不断获得监管部门批准，并持续创新以拓展适应症，这些都持续推动全球市场成长。

市场动态

成长因素

关键成长驱动因素是全球神经系统疾病负担的日益加重。根据世界卫生组织的数据（2024年3月），到2021年，头痛疾病将影响全球约40%的人口（约31亿人）。慢性偏头痛是全球主要的致残原因之一，因此对有效的神经毒素疗法的需求日益增长。肉毒桿菌毒素可显着降低偏头痛发作的频率和严重程度，使其成为传统疗法无效的患者的重要选择。

限制

高昂的治疗费用和低收入国家有限的保险覆盖范围阻碍了市场准入。例如，根据2023年发表在 "Cureus" 杂誌上的一项研究，肉毒桿菌治疗偏头痛的年费用约为3000美元，这对许多患者来说过于昂贵。此外，诸如眼睑下垂、肌肉无力和颈部疼痛等副作用会影响患者的依从性，并影响治疗选择。

机会

越来越多的研究探讨了神经毒素在精神医学中的应用，展现出巨大的潜力。研究表明，A型肉毒桿菌毒素（BoNT/A）可能透过杏仁核调节情绪处理，从而在重度忧郁症（MDD）、创伤后压力症候群（PTSD）和社交焦虑症等疾病中具有潜在的治疗价值。 2024年3月，Healis Therapeutics与麻省总医院合作，启动了CKDB-501A（一种A型肉毒桿菌毒素（BoNT/A）神经调节剂）治疗多种神经精神疾病的临床试验。

挑战

生物相似药的兴起加剧了价格竞争，构成了一项重大挑战。 2024年9月，永旺生物製药（AEON BioPharma）透过FDA的351(k)途径推进了ABP-450的研发，这是一种旨在达到肉毒桿菌毒素等效性的生物类似药。随着生物相似药进入市场，品牌神经毒素生产商面临价格压力，并转向更具成本效益的替代方案。

市场趋势

一个新兴的关键趋势是开发无针神经毒素输送系统。许多患者反映注射治疗会引起焦虑和不适，尤其是在原发性腋窝多汗症等疾病。 Dermata Therapeutics和Revance等公司正在评估局部神经毒素製剂作为替代方案。 2025年1月，这两家公司合作探索将Xyngari（局部海绵粉）和Daxxify组合用于局部神经毒素输送。

市场区隔亮点

按类型

2024年，A型肉毒桿菌毒素凭藉其大量核准的治疗产品占市场主导地位。近期获准的产品，例如Merz Pharma的Xeomin（于2023年在澳洲获准），进一步巩固了该细分市场的领先地位。

B型肉毒桿菌毒素虽然市占率较小，但透过持续的临床试验不断扩大其市场占有率。

按应用

由于肌肉痉挛发病率的上升以及痉挛治疗适应症的扩大，痉挛治疗占了最大的市场占有率。慢性偏头痛则因全球需求的成长而成为第二大细分市场。

按最终使用者

2024年，由于病患数量增加、报销制度的完善以及治疗能力的提升，医院将占市场主导地位。由于对神经系统疾病和治疗护理的巨大需求，专科诊所也随之发展。

区域展望

2024年，北美市场规模达到42.4亿美元，凭藉较高的患者认知度、强有力的报销政策和积极的临床试验，保持着其市场主导地位。由于持续的产品审批和治疗的广泛应用，美国仍然是最大的国内市场。

欧洲占第二大市场占有率，这主要得益于神经系统疾病盛行率的上升以及产品审批的增加，例如益普生公司Dysport于2022年获批的延期上市。

由于疾病盛行率的上升和持续的研发投入，亚太地区预计将实现最快成长。

拉丁美洲和中东/非洲地区在神经毒素疗法普及的推动下，将持续保持稳定成长。

目录

第一章：引言

第二章：摘要整理

第三章：市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机遇
  • 市场趋势

第四章：主要发现

  • 主要国家治疗量概览
  • 主要国家监理状况概览
  • 主要国家报销状况概览
  • 主要公司新产品发布
  • 主要公司在研产品线分析

第五章：全球治疗性神经毒素市场分析、洞察与预测（2019-2032）

  • 市场分析、洞察与预测 - 按类型划分
    • A型肉毒桿菌毒素
    • B型肉毒桿菌
  • 市场分析、洞察与预测 - 按应用划分
    • 额纹
    • 眉间纹
    • 鱼尾纹
    • 其他
  • 市场分析、洞察与预测 - 按最终用户划分
    • 专科诊所及皮肤科诊所
    • 医院和诊所
    • 其他
  • 市场分析、洞察与预测 - 按地区划分
    • 北美
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲

第六章 北美治疗性神经毒素市场分析、洞察与预测（2019-2032）

  • 依国家划分
    • 美国
    • 加拿大

第七章 欧洲治疗性神经毒素市场分析、洞察与预测（2019-2032）

  • 依国家划分
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 义大利
    • 斯堪的纳维亚
    • 乌克兰
    • 欧洲其他地区

第八章 亚太地区治疗性神经毒素市场分析、洞察与预测（2019-2032）

  • 依国家划分
    • 日本
    • 中国
    • 印度
    • 澳大利亚
    • 韩国
    • 泰国
    • 台湾
    • 亚太其他地区

第九章：拉丁美洲治疗性神经毒素市场分析、洞察与预测（2019-2032）

  • 依国家划分
    • 巴西
    • 墨西哥
    • 智利
    • 哥伦比亚
    • 拉丁美洲其他地区

第十章：中东和非洲治疗性神经毒素市场分析、洞察与预测（2019-2032）

  • 依国家划分
    • 埃及
    • 伊朗
    • 土耳其
    • 黎巴嫩
    • 阿拉伯联合大公国
    • 沙乌地阿拉伯
    • 南非
    • 其他中东和非洲国家

第11章 竞争分析

  • 全球市占率分析（2024）
  • 公司简介
    • 艾伯维公司（Allergen Therapeutics）
    • 益普生製药
    • 默兹製药
    • HUGEL公司
    • Evolus公司
    • 高德美
    • 瑞凡斯
    • Supernus製药
    • 上海復星医药（集团）有限公司
    • 大王製药股份有限公司
Product Code: FBI113754

Growth Factors of therapeutic neurotoxin Market

The global therapeutic neurotoxin market is expanding steadily, driven by the rising prevalence of neurological disorders and rapidly growing adoption of botulinum toxin therapies across medical specialties. According to the report, the market size reached USD 5.86 billion in 2024, is projected to rise to USD 6.34 billion in 2025, and is expected to reach USD 11.22 billion by 2032, reflecting a CAGR of 8.5% during the forecast period. In 2024, North America held a dominant 72.6% share of the market owing to advanced healthcare systems and early adoption of therapeutic neurotoxins across various indications.

Therapeutic neurotoxins-primarily botulinum toxin types A and B-are widely used to manage neurological conditions such as chronic migraines, cervical dystonia, blepharospasm, spasticity, and overactive bladder. Their mechanism involves blocking neuromuscular transmission, thereby reducing muscle overactivity and associated symptoms. Increasing regulatory approvals for expanded uses and continuous innovation by key companies such as AbbVie Inc., Ipsen Pharma, Merz Pharma, and Revance Therapeutics continue to support global market growth.

Market Dynamics

Drivers

The primary growth driver is the increasing global burden of neurological disorders. WHO data (March 2024) reported that headache disorders affected approximately 40% of the global population, representing nearly 3.10 billion individuals in 2021. Chronic migraine is one of the leading causes of disability worldwide, thereby increasing the demand for effective neurotoxin-based therapies. Botulinum toxin significantly reduces migraine frequency and severity, making it a critical option for patients who do not respond to conventional therapies.

Restraints

High treatment costs and limited reimbursement in low-income countries restrict market accessibility. For example, a 2023 study published in Cureus found that Botox therapy for migraines costs around USD 3,000 per year, making it unaffordable for many patients. Additionally, side effects such as eyelid ptosis, muscle weakness, and neck pain impact patient adherence and influence treatment preferences.

Opportunities

Growing research exploring neurotoxin use in psychiatry presents substantial opportunities. Studies indicate that Botulinum toxin type A (BoNT/A) may modulate emotional processing through the amygdala, creating potential therapeutic value in conditions such as major depressive disorder (MDD), PTSD, and social anxiety disorder. In March 2024, Healis Therapeutics partnered with Massachusetts General Hospital to begin clinical trials for CKDB-501A, a BoNT/A neuromodulator for multiple neuropsychiatric conditions.

Challenges

The rise of biosimilars poses a strong challenge by increasing price competition. In September 2024, AEON Biopharma advanced its ABP-450 biosimilar through the FDA's 351(k) pathway, targeting equivalence to BOTOX. As biosimilars enter the market, branded neurotoxin manufacturers face pricing pressure and a shift toward more cost-effective alternatives.

Market Trends

A major emerging trend is the development of needle-free neurotoxin delivery systems. Many patients experience anxiety and discomfort with injectable treatments, particularly for conditions such as primary axillary hyperhidrosis. Companies like Dermata Therapeutics and Revance are evaluating topical neurotoxin applications as an alternative. In January 2025, both companies collaborated to explore a combination of Xyngari (topical Spongilla powder) with Daxxify for topical neurotoxin delivery.

Segmentation Highlights

By Type

Botulinum toxin type A dominated the market in 2024 due to a large number of approved therapeutic products. Recent approvals, such as Merz Pharma's 2023 approval for Xeomin in Australia, contribute to segment leadership.

Botulinum toxin type B holds a smaller share but continues expanding via ongoing clinical trials.

By Application

The spasticity segment held the largest share owing to the rising incidence of muscular spasticity and increasing label expansions for spasticity treatment. Chronic migraine represented the second-largest segment due to extensive global demand.

By End User

Hospitals dominated the market in 2024 due to higher patient inflow, improved reimbursement, and advanced treatment capabilities. Specialty clinics followed with significant demand for targeted neurological and therapeutic care.

Regional Outlook

In 2024, North America generated USD 4.24 billion, maintaining its dominance through high patient awareness, strong reimbursement policies, and active clinical trials. The U.S. remains the largest national market with continuous product approvals and broad therapeutic adoption.

Europe holds the second-largest share, driven by rising neurological disease prevalence and product approvals such as Ipsen's Dysport label expansion in 2022.

Asia Pacific is projected to grow fastest due to increasing disease prevalence and ongoing R&D investments.

Latin America and the Middle East & Africa continue to expand steadily, supported by increasing access to neurotoxin therapies.

Conclusion

Growing from USD 5.86 billion in 2024 to USD 11.22 billion by 2032, the therapeutic neurotoxin market is poised for strong long-term growth fueled by increasing neurological disease burdens, expanding clinical applications, and continuous innovation from key industry players.

Segmentation By Type

  • Botulinum Toxin Type A
  • Botulinum Toxin Type B

By Application

  • Chronic Migraine
  • Spasticity
  • Overactive Bladder
  • Cervical Dystonia
  • Blepharospasm
  • Others

By End-user

  • Hospitals
  • Specialty Clinics
  • Others

By Region

  • North America (By Type, Application, End-user, and Country)
    • U.S. (By Application)
    • Canada (By Application)
  • Europe (By Type, Application, End-user, and Country/Sub-Region)
    • U.K. (By Application)
    • Germany (By Application)
    • France (By Application)
    • Italy (By Application)
    • Spain (By Application)
    • Scandinavia (By Application)
    • Ukraine (By Application)
    • Rest of Europe (By Application)
  • Asia Pacific (By Type, Application, End-user, and Country/Sub-Region)
    • Japan (By Application)
    • China (By Application)
    • India (By Application)
    • Australia (By Application)
    • South Korea (By Application)
    • Thailand (By Application)
    • Taiwan (By Application)
    • Rest of Asia Pacific (By Application)
  • Latin America (By Type, Application, End-user, and Country/Sub-Region)
    • Brazil (By Application)
    • Mexico (By Application)
    • Colombia (By Application)
    • Argentina (By Application)
    • Venezuela (By Application)
    • Chile (By Application)
    • Rest of Latin America (By Application)
  • Middle East & Africa (By Type, Application, End-user, and Country/Sub-Region)
    • UAE (By Application)
    • Saudi Arabia (By Application)
    • Turkey (By Application)
    • Egypt (By Application)
    • Lebanon (By Application)
    • Iran (By Application)
    • Rest of GCC (By Application)
    • South Africa (By Application)
    • Rest of the Middle East & Africa (By Application)

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Overview of the Number of Therapeutic Procedures, By Key Countries
  • 4.2. Overview of Regulatory Scenario, By Key Countries
  • 4.3. Overview of Reimbursement Scenario, By Key Countries
  • 4.4. New Product Launches, By Key Players
  • 4.5. Pipeline Analysis, By Key Players

5. Global Therapeutic Neurotoxin Market Analysis, Insights and Forecast, 2019-2032

  • 5.1. Market Analysis, Insights and Forecast - By Type
    • 5.1.1. Botulinum Toxin Type A
    • 5.1.2. Botulinum Toxin Type B
  • 5.2. Market Analysis, Insights and Forecast - By Application
    • 5.2.1. Forehead Wrinkles
    • 5.2.2. Glabellar Lines
    • 5.2.3. Crow's Feet
    • 5.2.4. Others
  • 5.3. Market Analysis, Insights and Forecast - By End-User
    • 5.3.1. Specialty & Dermatology Clinics
    • 5.3.2. Hospitals & Clinics
    • 5.3.3. Others
  • 5.4. Market Analysis, Insights and Forecast - Region
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Latin America
    • 5.4.5. Middle East & Africa

6. North America Therapeutic Neurotoxin Market Analysis, Insights and Forecast, 2019-2032

  • 6.1. Market Analysis, Insights and Forecast - By Type
    • 6.1.1. Botulinum Toxin Type A
    • 6.1.2. Botulinum Toxin Type B
  • 6.2. Market Analysis, Insights and Forecast - By Application
    • 6.2.1. Forehead Wrinkles
    • 6.2.2. Glabellar Lines
    • 6.2.3. Crow's Feet
    • 6.2.4. Others
  • 6.3. Market Analysis, Insights and Forecast - By End-User
    • 6.3.1. Specialty & Dermatology Clinics
    • 6.3.2. Hospitals & Clinics
    • 6.3.3. Others
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
    • 6.4.2. Canada

7. Europe Therapeutic Neurotoxin Market Analysis, Insights and Forecast, 2019-2032

  • 7.1. Market Analysis, Insights and Forecast - By Type
    • 7.1.1. Botulinum Toxin Type A
    • 7.1.2. Botulinum Toxin Type B
  • 7.2. Market Analysis, Insights and Forecast - By Application
    • 7.2.1. Forehead Wrinkles
    • 7.2.2. Glabellar Lines
    • 7.2.3. Crow's Feet
    • 7.2.4. Others
  • 7.3. Market Analysis, Insights and Forecast - By End-User
    • 7.3.1. Specialty & Dermatology Clinics
    • 7.3.2. Hospitals & Clinics
    • 7.3.3. Others
  • 7.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.4.1. U.K.
    • 7.4.2. Germany
    • 7.4.3. France
    • 7.4.4. Spain
    • 7.4.5. Italy
    • 7.4.6. Scandinavia
    • 7.4.7. Ukraine
    • 7.4.8. Rest of Europe

8. Asia Pacific Therapeutic Neurotoxin Market Analysis, Insights and Forecast, 2019-2032

  • 8.1. Market Analysis, Insights and Forecast - By Type
    • 8.1.1. Botulinum Toxin Type A
    • 8.1.2. Botulinum Toxin Type B
  • 8.2. Market Analysis, Insights and Forecast - By Application
    • 8.2.1. Forehead Wrinkles
    • 8.2.2. Glabellar Lines
    • 8.2.3. Crow's Feet
    • 8.2.4. Others
  • 8.3. Market Analysis, Insights and Forecast - By End-User
    • 8.3.1. Specialty & Dermatology Clinics
    • 8.3.2. Hospitals & Clinics
    • 8.3.3. Others
  • 8.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.4.1. Japan
    • 8.4.2. China
    • 8.4.3. India
    • 8.4.4. Australia
    • 8.4.5. South Korea
    • 8.4.6. Thailand
    • 8.4.7. Taiwan
    • 8.4.8. Rest of Asia Pacific

9. Latin America Therapeutic Neurotoxin Market Analysis, Insights and Forecast, 2019-2032

  • 9.1. Market Analysis, Insights and Forecast - By Type
    • 9.1.1. Botulinum Toxin Type A
    • 9.1.2. Botulinum Toxin Type B
  • 9.2. Market Analysis, Insights and Forecast - By Application
    • 9.2.1. Forehead Wrinkles
    • 9.2.2. Glabellar Lines
    • 9.2.3. Crow's Feet
    • 9.2.4. Others
  • 9.3. Market Analysis, Insights and Forecast - By End-User
    • 9.3.1. Specialty & Dermatology Clinics
    • 9.3.2. Hospitals & Clinics
    • 9.3.3. Others
  • 9.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.4.1. Brazil
    • 9.4.2. Mexico
    • 9.4.3. Chile
    • 9.4.4. Colombia
    • 9.4.5. Rest of Latin America

10. Middle East & Africa Therapeutic Neurotoxin Market Analysis, Insights and Forecast, 2019-2032

  • 10.1. Market Analysis, Insights and Forecast - By Type
    • 10.1.1. Botulinum Toxin Type A
    • 10.1.2. Botulinum Toxin Type B
  • 10.2. Market Analysis, Insights and Forecast - By Application
    • 10.2.1. Forehead Wrinkles
    • 10.2.2. Glabellar Lines
    • 10.2.3. Crow's Feet
    • 10.2.4. Others
  • 10.3. Market Analysis, Insights and Forecast - By End-User
    • 10.3.1. Specialty & Dermatology Clinics
    • 10.3.2. Hospitals & Clinics
    • 10.3.3. Others
  • 10.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.4.1. Egypt
    • 10.4.2. Iran
    • 10.4.3. Turkey
    • 10.4.4. Lebanon
    • 10.4.5. UAE
    • 10.4.6. Saudi Arabia
    • 10.4.7. South Africa
    • 10.4.8. Rest of Middle East and Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2024)
  • 11.2. Company Profiles
    • 11.2.1. AbbVie Inc. (Allergen Therapeutics)
      • 11.2.1.1. Overview
      • 11.2.1.2. Products & services
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. Ipsen Pharma
      • 11.2.2.1. Overview
      • 11.2.2.2. Products & services
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. Merz Pharma
      • 11.2.3.1. Overview
      • 11.2.3.2. Products & services
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. HUGEL, Inc.
      • 11.2.4.1. Overview
      • 11.2.4.2. Products & services
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Evolus, Inc.
      • 11.2.5.1. Overview
      • 11.2.5.2. Products & services
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. GALDERMA
      • 11.2.6.1. Overview
      • 11.2.6.2. Products & services
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. REVANCE
      • 11.2.7.1. Overview
      • 11.2.7.2. Products & services
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. Supernus Pharmaceuticals, Inc.
      • 11.2.8.1. Overview
      • 11.2.8.2. Products & services
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)
    • 11.2.9. Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
      • 11.2.9.1. Overview
      • 11.2.9.2. Products & services
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. Financials (Based on Availability)
    • 11.2.10. DAEWOONG PHARMACEUTICAL CO., LTD
      • 11.2.10.1. Overview
      • 11.2.10.2. Products & services
      • 11.2.10.3. SWOT Analysis
      • 11.2.10.4. Recent Developments
      • 11.2.10.5. Strategies
      • 11.2.10.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Therapeutic Neurotoxin Market Revenue (USD billion) Forecast, by Type, 2019-2032
  • Table 2: Global Therapeutic Neurotoxin Market Revenue (USD billion) Forecast, by Application, 2019-2032
  • Table 3: Global Therapeutic Neurotoxin Market Revenue (USD billion) Forecast, by End-User, 2019-2032
  • Table 4: Global Therapeutic Neurotoxin Market Revenue (USD billion) Forecast, by Region, 2019-2032
  • Table 5: North America Therapeutic Neurotoxin Market Revenue (USD billion) Forecast, by Type, 2019-2032
  • Table 6: North America Therapeutic Neurotoxin Market Revenue (USD billion) Forecast, by Application, 2019-2032
  • Table 7: North America Therapeutic Neurotoxin Market Revenue (USD billion) Forecast, by End-User, 2019-2032
  • Table 8: North America Therapeutic Neurotoxin Market Revenue (USD billion) Forecast, by Country, 2019-2032
  • Table 9: Europe Therapeutic Neurotoxin Market Revenue (USD billion) Forecast, by Type, 2019-2032
  • Table 10: Europe Therapeutic Neurotoxin Market Revenue (USD billion) Forecast, by Application, 2019-2032
  • Table 11: Europe Therapeutic Neurotoxin Market Revenue (USD billion) Forecast, by End-User, 2019-2032
  • Table 12: Europe Therapeutic Neurotoxin Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2019-2032
  • Table 13: Asia Pacific Therapeutic Neurotoxin Market Revenue (USD billion) Forecast, by Type, 2019-2032
  • Table 14: Asia Pacific Therapeutic Neurotoxin Market Revenue (USD billion) Forecast, by Application, 2019-2032
  • Table 15: Asia Pacific Therapeutic Neurotoxin Market Revenue (USD billion) Forecast, by End-User, 2019-2032
  • Table 16: Asia Pacific Therapeutic Neurotoxin Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2019-2032
  • Table 17: Latin America Therapeutic Neurotoxin Market Revenue (USD billion) Forecast, by Type, 2019-2032
  • Table 18: Latin America Therapeutic Neurotoxin Market Revenue (USD billion) Forecast, by Application, 2019-2032
  • Table 19: Latin America Therapeutic Neurotoxin Market Revenue (USD billion) Forecast, by End-User, 2019-2032
  • Table 20: Latin America Therapeutic Neurotoxin Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2019-2032
  • Table 21: Middle East & Africa Therapeutic Neurotoxin Market Revenue (USD billion) Forecast, by Type, 2019-2032
  • Table 22: Middle East & Africa Therapeutic Neurotoxin Market Revenue (USD billion) Forecast, by Application, 2019-2032
  • Table 23: Middle East & Africa Therapeutic Neurotoxin Market Revenue (USD billion) Forecast, by End-User, 2019-2032
  • Table 24: Middle East & Africa Therapeutic Neurotoxin Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2019-2032

List of Figures

  • Figure 1: Global Therapeutic Neurotoxin Market Revenue Breakdown (USD billion, %) by Region, 2024 & 2032
  • Figure 2: Global Therapeutic Neurotoxin Market Value Share (%), by Type, 2024 & 2032
  • Figure 3: Global Therapeutic Neurotoxin Market Value Share (%), by Application, 2024 & 2032
  • Figure 4: Global Therapeutic Neurotoxin Market Value Share (%), by End-User, 2024 & 2032
  • Figure 5: Global Therapeutic Neurotoxin Market Value Share (%), by Region, 2024 & 2032
  • Figure 6: North America Therapeutic Neurotoxin Market Value (USD billion), by Type, 2024 & 2032
  • Figure 7: North America Therapeutic Neurotoxin Market Value Share (%), by Type, 2024
  • Figure 8: North America Therapeutic Neurotoxin Market Value (USD billion), by Application, 2024 & 2032
  • Figure 9: North America Therapeutic Neurotoxin Market Value Share (%), by Application, 2024
  • Figure 10: North America Therapeutic Neurotoxin Market Value (USD billion), by End-User, 2024 & 2032
  • Figure 11: North America Therapeutic Neurotoxin Market Value Share (%), by End-User, 2024
  • Figure 12: North America Therapeutic Neurotoxin Market Value (USD billion), by Country, 2024 & 2032
  • Figure 13: North America Therapeutic Neurotoxin Market Value Share (%), by Country, 2024
  • Figure 14: Europe Therapeutic Neurotoxin Market Value (USD billion), by Type, 2024 & 2032
  • Figure 15: Europe Therapeutic Neurotoxin Market Value Share (%), by Type, 2024
  • Figure 16: Europe Therapeutic Neurotoxin Market Value (USD billion), by Application, 2024 & 2032
  • Figure 17: Europe Therapeutic Neurotoxin Market Value Share (%), by Application, 2024
  • Figure 18: Europe Therapeutic Neurotoxin Market Value (USD billion), by End-User, 2024 & 2032
  • Figure 19: Europe Therapeutic Neurotoxin Market Value Share (%), by End-User, 2024
  • Figure 20: Europe Therapeutic Neurotoxin Market Value (USD billion), by Country/ Sub-region, 2024 & 2032
  • Figure 21: Europe Therapeutic Neurotoxin Market Value Share (%), by Country/ Sub-region, 2024
  • Figure 22: Asia Pacific Therapeutic Neurotoxin Market Value (USD billion), by Type, 2024 & 2032
  • Figure 23: Asia Pacific Therapeutic Neurotoxin Market Value Share (%), by Type, 2024
  • Figure 24: Asia Pacific Therapeutic Neurotoxin Market Value (USD billion), by Application, 2024 & 2032
  • Figure 25: Asia Pacific Therapeutic Neurotoxin Market Value Share (%), by Application, 2024
  • Figure 26: Asia Pacific Therapeutic Neurotoxin Market Value (USD billion), by End-User, 2024 & 2032
  • Figure 27: Asia Pacific Therapeutic Neurotoxin Market Value Share (%), by End-User, 2024
  • Figure 28: Asia Pacific Therapeutic Neurotoxin Market Value (USD billion), by Country/ Sub-region, 2024 & 2032
  • Figure 29: Asia Pacific Therapeutic Neurotoxin Market Value Share (%), by Country/ Sub-region, 2024
  • Figure 30: Latin America Therapeutic Neurotoxin Market Value (USD billion), by Type, 2024 & 2032
  • Figure 31: Latin America Therapeutic Neurotoxin Market Value Share (%), by Type, 2024
  • Figure 32: Latin America Therapeutic Neurotoxin Market Value (USD billion), by Application, 2024 & 2032
  • Figure 33: Latin America Therapeutic Neurotoxin Market Value Share (%), by Application, 2024
  • Figure 34: Latin America Therapeutic Neurotoxin Market Value (USD billion), by End-User, 2024 & 2032
  • Figure 35: Latin America Therapeutic Neurotoxin Market Value Share (%), by End-User, 2024
  • Figure 36: Latin America Therapeutic Neurotoxin Market Value (USD billion), by Country/ Sub-region, 2024 & 2032
  • Figure 37: Latin America Therapeutic Neurotoxin Market Value Share (%), by Country/ Sub-region, 2024
  • Figure 38: Middle East & Africa Therapeutic Neurotoxin Market Value (USD billion), by Type, 2024 & 2032
  • Figure 39: Middle East & Africa Therapeutic Neurotoxin Market Value Share (%), by Type, 2024
  • Figure 40: Middle East & Africa Therapeutic Neurotoxin Market Value (USD billion), by Application, 2024 & 2032
  • Figure 41: Middle East & Africa Therapeutic Neurotoxin Market Value Share (%), by Application, 2024
  • Figure 42: Middle East & Africa Therapeutic Neurotoxin Market Value (USD billion), by End-User, 2024 & 2032
  • Figure 43: Middle East & Africa Therapeutic Neurotoxin Market Value Share (%), by End-User, 2024
  • Figure 44: Middle East & Africa Therapeutic Neurotoxin Market Value (USD billion), by Country/ Sub-region, 2024 & 2032
  • Figure 45: Middle East & Africa Therapeutic Neurotoxin Market Value Share (%), by Country/ Sub-region, 2024
  • Figure 46: Global Therapeutic Neurotoxin Market Share (%), by Company, 2024